Effectiveness of Liposomial Ozonized-Oil for Cataract Surgery

Sponsor
University of Molise (Other)
Overall Status
Completed
CT.gov ID
NCT04087733
Collaborator
Azienda Policlinico Umberto I, Roma (Other), Università degli Studi del Molise, Clinica Oculistica (Other), Clinica Mediterranea, Napoli (Other), Ospedale Santa Croce-Carle Cuneo (Other), Centro Medico Oculistico ALSO, Saronno (Other), Fondazione G.B. Bietti, IRCCS , Roma (Other), Ospedale San Carlo di Nancy, Roma (Other), Centro oftalmologico LASERVISTA, Caserta (Other), Casa di cura GEPOS, Telese (Other), Azienda Ospedaliero-Universitaria Consorziale, Bari (Other), Ospedale generale regionale F. Miulli, Acquaviva delle Fonti (Other), Azienda Ospedaliera Universitaria Mater Domini, Catanzaro (Other), Ospedale Policlinico Casilino, Roma (Other), Ospedale G. Panico, Tricase (Other), Studio oculistico Laborante (Other), Studio oculistico Franchini (Other), U.C.O Ospedali Civico di Cristina Benfratelli (Other), A.O.U. Città della Salute e della Scienza - Molinette Hospital (Other)
200
1
2
12
16.7

Study Details

Study Description

Brief Summary

Evaluation of the antimicrobial efficacy of a liposomal ozone-based solution (OZODROP®) , vs placebo in 200 patients undergoing cataract surgery by phacoemulsification .

The clinical trial will last 3 days of treatment per patient. The conjunctival swab will be taken for each of the two eyes (in treatment and control) at T0 (before starting the treatment - 3 days before the cataract surgery) and at T3 (after 3 days of treatment - immediately before the cataract surgery). The last OZODROP instillation will take place 10 minutes before taking the sample.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

The aim of the study is to assess the efficacy of a liposomal ozone-based solution (OZODROP®) in the preparation of the patient for cataract surgery, by evaluating the reduction of bacterial colonization of the conjunctiva.

The study will be carried out at 18 surgical centers located throughout the national territory and will be conducted in accordance with the recommendations of Italian ethics committees.

An informed consent will be provided to all study participants. 400 eyes of 200 patients undergoing cataract surgery by phacoemulsification will be included in the study. The clinical sample is divided into two groups, study group which will include treated and (GS) and control group (GC) eyes. The study group will be treated with OZODROP®, an isotonic ophthalmic solution composed of 0.5% ozonized oil in liposomes and hypromellose, while the GC will receive saline solution.

At the time of recruitment, all eyes will undergo a complete examination, as usual, and the patient enrolled in the study will be shown how to proceed.

The study includes 2 times, (T0) and (T3), equal for both groups in the study. 3 days before the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in the study, one in the eye to be operated and one in the control eye, who will be kept at a controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than, starting on the day of collection, the patients will instill the OZODROP® eye drops in the eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00, h21: 00), while the untreated contralateral eye will serve as a control.Immediately before the cataract surgery (T3), the patients enrolled in the study will again receive two conjunctival swabs, one in the eye to be operated and one in the control eye. The last OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the Microbiology laboratory. The reduction of conjunctival microbial flora, expressed as CFU, will be evaluated.

Through the analysis of the parameters in the study, a significant reduction in the microbial flora of the conjunctiva is expected in patients undergoing treatment with OZODROP®.

Study Design

Study Type:
Interventional
Actual Enrollment :
200 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
GROUP / TREATED EYE (OZODROP® ): OZODROP® (ozonized oil 0.5% in liposomes) ophthalmic solution, 2 drops 4 times a day. OZODROP® will be instilled in the eye that will have to undergo cataract surgery. GROUP / CONTROL EYE: saline solution 2 drops 4 times a day. As a check it will be used the contralateral eye that will not have to undergo cataract surgery.GROUP / TREATED EYE (OZODROP® ): OZODROP® (ozonized oil 0.5% in liposomes) ophthalmic solution, 2 drops 4 times a day. OZODROP® will be instilled in the eye that will have to undergo cataract surgery. GROUP / CONTROL EYE: saline solution 2 drops 4 times a day. As a check it will be used the contralateral eye that will not have to undergo cataract surgery.
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Effectiveness of Liposomial Ozonized-Oil on Ocular Microbial Flora Before Cataract Surgery
Actual Study Start Date :
Oct 1, 2019
Actual Primary Completion Date :
Jun 30, 2020
Actual Study Completion Date :
Sep 30, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: GROUP / TREATED EYE

OZODROP® (ozonized oil 0.5% in liposomes) ophthalmic solution, 2 drops 4 times a day. OZODROP® will be instilled in the eye that will have to undergo cataract surgery.

Drug: OZODROP
3 days before the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in the study, one in the eye to be operated and one in the control eye, who will be kept at a controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than, starting on the day of collection, the patients will instill the OZODROP® eye drops in the eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00, h21: 00), while the contralateral eye will be treated with a saline solution and it will serve as a control. Immediately before the cataract surgery (T3), the patients enrolled in the study will again receive two conjunctival swabs, one in the eye to be operated and one in the control eye. The last OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the Microbiology laboratory
Other Names:
  • liposomal ozone-based solution
  • No Intervention: GROUP / CONTROL EYE

    Saline solution 2 drops 4 times a day. As a check it will be used the contralateral eye that will not have to undergo cataract surgery.

    Outcome Measures

    Primary Outcome Measures

    1. Reduction of conjunctival bacterial load assessed by CFU (Colony Forming Units) using Ozodrop in 200 patients before cataract surgery [3 days]

      Reduction/eradication of conjunctival bacterial load in patients treated with ozodrop for three days before undergoing cataract surgery. For the microbiological evaluation, the conjunctival swabs taken at T0 (before starting OZODROP instillation) and T3 (after instilling OZODROP 4 times/day for three days) will be sent to the Microbiology laboratory to be seeded, enriched and then isolated the different species under examination by suitable selective media. The different samples will be analyzed according to the routine methods used in microbiology. The untreated contralateral eye will serve as a control.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Age over 18 years

    2. Patients eligible for cataract surgery

    3. Willingness to participate in the study following the indications

    Exclusion Criteria:
    1. Use of topical and / or systemic antibiotics and other topical antiseptics during the study

    2. Presence of topical ocular therapies that cannot be suspended for the entire duration of the study

    3. Ongoing ocular or systemic inflammatory or infectious processes

    4. Hypersensitivity to the constituents of the preparation in study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Molise Campobasso Italy

    Sponsors and Collaborators

    • University of Molise
    • Azienda Policlinico Umberto I, Roma
    • Università degli Studi del Molise, Clinica Oculistica
    • Clinica Mediterranea, Napoli
    • Ospedale Santa Croce-Carle Cuneo
    • Centro Medico Oculistico ALSO, Saronno
    • Fondazione G.B. Bietti, IRCCS , Roma
    • Ospedale San Carlo di Nancy, Roma
    • Centro oftalmologico LASERVISTA, Caserta
    • Casa di cura GEPOS, Telese
    • Azienda Ospedaliero-Universitaria Consorziale, Bari
    • Ospedale generale regionale F. Miulli, Acquaviva delle Fonti
    • Azienda Ospedaliera Universitaria Mater Domini, Catanzaro
    • Ospedale Policlinico Casilino, Roma
    • Ospedale G. Panico, Tricase
    • Studio oculistico Laborante
    • Studio oculistico Franchini
    • U.C.O Ospedali Civico di Cristina Benfratelli
    • A.O.U. Città della Salute e della Scienza - Molinette Hospital

    Investigators

    • Principal Investigator: Ciro Costagliola, University of Molise

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    University of Molise
    ClinicalTrials.gov Identifier:
    NCT04087733
    Other Study ID Numbers:
    • 0003-08-2018
    First Posted:
    Sep 12, 2019
    Last Update Posted:
    Feb 11, 2021
    Last Verified:
    Feb 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 11, 2021